Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer.
Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer.
复制标题
DOI：
10.1016/s1040-8428(02)00105-1
复制
发表时间：
2002-12
期刊：
影响因子：
--
通讯作者：
H. Lück;H. Roché
中科院分区：
文献类型：
--
作者：
H. Lück;H. Roché
每周一次密集剂量紫杉醇治疗乳腺癌的基本原理是，通过使分裂的肿瘤细胞更持续地暴露于细胞毒性药物，更频繁地施用较中等剂量的紫杉醇可能比不频繁施用较大剂量的紫杉醇取得更好的疗效。每周一次紫杉醇已成功用于治疗晚期乳腺癌，作为单药治疗、联合化疗、放疗和免疫调节药物（如曲妥珠单抗）。这些研究中的许多患者之前接受过化疗方案。尽管如此，每周一次紫杉醇单药治疗的缓解率高达 86%，联合治疗的缓解率高达 87%，与放疗联合治疗的缓解率高达 100%。每周给予紫杉醇和抗 HER2 人源化单克隆抗体曲妥珠单抗，对侵袭性 HER2 阳性肿瘤患者的缓解率为 50-82%。紫杉醇具有中等毒性。其主要的剂量限制性毒性是中性粒细胞减少症和周围神经病变，但这些通常是可以控制的。
The rationale for dose-dense weekly paclitaxel in the treatment of breast cancer is that more frequent delivery of more moderate doses may achieve greater efficacy than larger doses given less often through more sustained exposure of dividing tumor cells to cytotoxic drugs. Weekly paclitaxel has been used successfully in the treatment of advanced breast cancer, as single-agent therapy, in combination chemotherapy, with radiotherapy and with immunomodulating drugs, such as trastuzumab. Many of the patients in these studies have received previous chemotherapy regimens. Nevertheless, response rates with weekly paclitaxel up to 86% have been achieved with single-agent therapy, up to 87% with combination therapy and up to 100% when combined with radiotherapy. Paclitaxel given weekly together with the humanized monoclonal antibody against HER2, trastuzumab, has shown response rates of 50–82% in patients with aggressive HER2-positive tumors. Paclitaxel is associated with moderate toxicity. Its main dose-limiting toxicities are neutropenia and peripheral neuropathy, but these are generally manageable.